// App-Quantinova.ai

4140 : sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.

Researchers

Presenter

  • Enrique Grande

Principal Investigators

  • Oriol Casanovas

  • Julie Earl

  • Jesus Garca-Donas

  • Luis Ortega

  • Juan Jose Diez

  • Ainara Soria Rivas

  • Jaume Capdevila

  • Daniel E. Castellano

  • Rocio Garcia-Carbonero

  • Alex Teule

  • Ignacio Duran

  • Jose Fuster

  • Isabel Sevilla

  • Pilar Escudero

  • Javier Sastre

Medical Centers

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Virgen del Rocio/Instituto de Biomedicina de Sevilla, Seville, Spain

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • IBIMA-Hospital Regional Universitario y Virgen de la Victoria, Malaga, Spain

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Ramon y Cajal University Hospital, Madrid, Spain

  • University Hospital Son Espases, Palma De Mallorca, Spain

  • Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • Chromogranin A

  • Circulating tumor cells

  • Proliferation marker protein Ki-67

  • Vascular endothelial growth factor A

Drug/Treatment

  • Somatostatin

  • Pazopanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01280201

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved